Duligotuzumab
Duligotuzumab
Duligotuzumab (pronunciation: doo-li-goh-TOO-zoo-mab) is a monoclonal antibody designed for the treatment of cancer. It is a type of biological therapy that targets the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2).
Etymology
The name "Duligotuzumab" is derived from the International Nonproprietary Names (INN), where "zu" denotes humanized, "mab" stands for monoclonal antibody, and "Duli" is a unique stem.
Mechanism of Action
Duligotuzumab works by binding to the EGFR and HER2 on the surface of cancer cells, blocking them from receiving growth signals. This inhibits the growth and division of the cancer cells, and may also stimulate the body's immune system to attack the cancer cells.
Related Terms
- Monoclonal antibody: A type of protein made in the lab that can bind to substances in the body, including cancer cells.
- Epidermal growth factor receptor (EGFR): A protein found on the surface of some cells to which epidermal growth factor binds, causing the cells to divide.
- Human epidermal growth factor receptor 2 (HER2): A protein that in humans is encoded by the ERBB2 gene. It is known to be a proto-oncogene.
Clinical Trials
Duligotuzumab has been studied in clinical trials for the treatment of various types of cancer, including colorectal cancer, head and neck cancer, and non-small cell lung cancer (NSCLC). However, as of now, it is not yet approved by the Food and Drug Administration (FDA) or any other regulatory authority.
External links
- Medical encyclopedia article on Duligotuzumab
- Wikipedia's article - Duligotuzumab
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski